« Back Cancer Letters

Article in Press

Targeting apoptosis pathways in cancer by Chinese medicine

  • Min Li-Weber

      Affiliations

    • Corresponding Author InformationAddress: Tumor Immunology Program D030, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Tel.: +49 6221 423748; fax: +49 6221 411715.

Received 19 May 2010 ,Revised 11 July 2010 ,Accepted 13 July 2010. Published online 04 August 2010 Corrected Proof

References 

  1. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity. 2004;21:461–465
  2. Krammer PH, Arnold R, Lavrik I. Life and death in peripheral T cells. Nat. Rev. Immunol. 2007;7:532–542
  3. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset progression and therapy. Nat. Rev. Cancer. 2008;8:782–798
  4. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium–apoptosis link. Nat. Rev. Mol. Cell Biol. 2003;4:552–565
  5. Roderick HL, Cook SJ. Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival. Nat. Rev. Cancer. 2008;8:361–375
  6. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Disc. 2009;8:579–591
  7. Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell death. Nat. Rev. Mol. Cell Biol. 2007;8:405–413
  8. Billen LP, Shamas-Din A, Andrews DW. Bid: a Bax-like BH3 protein. Oncogene. 2008;1:93–104
  9. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006;7:988–994
  10. Galluzzi L, Larochette N, Zamzami N, Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene. 2006;25:4812–4830
  11. Wu H, Tschopp J, Lin SC. Smac mimetics and TNFalpha: a dangerous liaison?. Cell. 2007;131:655–658
  12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70
  13. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer. 2005;5:876–885
  14. Fulda S. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J. Cell Mol. Med. 2009;13:1221–1227
  15. U. Testa, TRAIL/TRAIL-R in hematologic malignancies, J. Cell Biochem., 2010 March 24 (Epub ahead of print).
  16. Turrens JF. Mitochondrial formation of reactive oxygen species. J. Physiol. 2003;552:335–344
  17. Szatrowski PT, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991;51:794–798
  18. Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell. 2006;10:175–176
  19. Huang Q, Lu G, Shen HM, Chung MC, Ong CN. Anti-cancer properties of anthraquinones from rhubarb. Med. Res. Rev. 2007;27:609–630
  20. Efferth T, Oesch F. Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem. Pharmacol. 2004;68:3–10
  21. Efferth T, Giaisi M, Merling A, Krammer PH, Li-Weber M. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One. 2007;2:e693
  22. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. 2002;32:1655–1660
  23. Borges F, Fernandes E, Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr. Med. Chem. 2002;9:195–217
  24. Meeran SM, Katiyar S, Katiyar SK. Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. Toxicol. Appl. Pharmacol. 2009;229:33–43
  25. Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat. Rev. 2009;35:57–68
  26. Townsend DM, Tew KD, Tapiero H. The importance of glutathione in human disease. Biomed. Pharmacother. 2003;57:145–155
  27. Kachadourian R, Day BJ. Flavonoid-induced glutathione depletion: potential implications for cancer treatment. Free Radic. Biol. Med. 2006;41:65–76
  28. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. GammaH2AX and cancer. Nat. Rev. Cancer. 2008;8:957–967
  29. Li PC, Lam E, Roos WP, Zdzienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res. 2008;68:4347–4351
  30. Liu Z, Liu Q, Xu B, Wu J, Guo C, Zhu F, et al. Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damage. Mutat. Res. 2009;662:75–83
  31. Lu C, Zhu F, Cho YY, Tang F, Zykova T, Ma WY, et al. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol. Cell. 2006;23:121–132
  32. Krey AK, Hahn FE. Berberine: complex with DNA. Science. 1969;166:755–757
  33. Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, et al. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999;284:339–343
  34. Baumann S, Fas SC, Giaisi M, Müller WW, Merling A, Gülow K, et al. Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCgamma1- and Ca2+-dependent apoptosis. Blood. 2008;111:2354–2363
  35. Montero M, Lobatón CD, Hernández-Sanmiguel E, Santodomingo J, Vay L, Moreno A, et al. Direct activation of the mitochondrial calcium uniporter by natural plant flavonoids. Biochem. J. 2004;384:19–24
  36. Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene. 2006;25:6800–6816
  37. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109:2700–2707
  38. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin. Cancer Res. 2007;13:2144–2150
  39. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer. 2005;5:297–309
  40. Zhu W, Ou Y, Li Y, Xiao R, Shu M, Zhou Y, et al. A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol. Pharmacol. 2009;75:812–819
  41. Salminen A, Lehtonen M, Paimela T, Kaarniranta K. Celastrol: Molecular targets of Thunder God Vine. Biochem. Biophys. Res. Commun. 2010;394:439–442
  42. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood. 2007;109:2727–2735
  43. Sung B, Park B, Yadav VR, Aggarwal BB. Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J. Biol. Chem. 2010;285:11498–11507
  44. Liao CH, Pan SL, Guh JH, Chang YL, Pai HC, Lin CH, et al. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis. 2005;26:968–975
  45. Takada Y, Kobayashi Y, Aggarwal BB. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J. Biol. Chem. 2005;280:17203–17212
  46. Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 2006;72:1493–1505
  47. Bubici C, Papa S, Dean K, Franzoso G. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene. 2006;25:6731–6748
  48. Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenlic acids. Free Radic. Biol. Med. 1996;20:933–956
  49. Fas SC, Baumann S, Zhu JY, Giaisi M, Treiber MK, Mahlknecht U, et al. Wogonin sensitizes resistant malignant cells to TNFα- and TRAIL-induced apoptosis. Blood. 2006;108:3700–3706
  50. Huang ST, Lee Y, Gullen EA, Cheng YC. Impacts of baicalein analogs with modification of the 6th position of A ring on the activity toward NF-kappaB-, AP-1-, or CREB-mediated transcription. Bioorg. Med. Chem. Lett. 2008;18:5046–5049
  51. Chou CC, Pan SL, Teng CM, Guh JH. Pharmacological evaluation of several major ingredients of Chinese herbal medicines in human hepatoma Hep3B cells. Eur. J. Pharm. Sci. 2003;19:403–412
  52. Romano G, Giordano A. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle. 2008;7:3664–3668
  53. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat. Rev. Cancer. 2010;10:254–266
  54. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009;283:125–134
  55. Leuenroth SJ, Crews CM. Triptolide-induced transcriptional arrest is associated with changes in nuclear substructure. Cancer Res. 2008;68:5257–5266
  56. Pan J. RNA polymerase - an important molecular target of triptolide in cancer cells. Cancer Lett. 2010;292:149–152
  57. Phatnani HP, Greenleaf AL. Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev. 2006;20:2922–2936
  58. Kim S, Salim AA, Swanson SM, Kinghorn AD. Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer Agents Med. Chem. 2006;6:319–345
  59. Zhu JY, Lavrik IN, Mahlknecht U, Giaisi M, Proksch P, Krammer PH, et al. The tradition Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of MAPK activities. Int. J. Cancer. 2007;121:1839–1846
  60. Zhu JY, Giaisi M, Köhler R, Müller WW, Mühleisen A, Proksch P, et al. Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. Cell Death Differ. 2009;16:1289–1299
  61. M. Bleumink, R. Köhler, M. Giaisi, P. Proksch, P.H. Krammer, M. Li-Weber, Rocaglamide breaks TRAIL-resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP Expression, Cell Death Differ. (2010), in press.
  62. Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, et al. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 2010;70:1951–1959
  63. Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M, et al. Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res. 2008;68:8918–8927
  64. Brenner D, Krammer PH, Arnold R. Concepts of activated T cell death. Crit. Rev. Oncol. Hematol. 2008;66:52–64
  65. Li-Weber M, Krammer PH. Function and regulation of CD95 (APO-1/Fas) ligand in the immune system. Semin. Immunol. 2003;15:145–157
  66. Proksch P, Giaisi M, Treiber MK, Palfi K, Merling A, Spring H, et al. Rocaglamide derivatives are immunosuppressive phytochemicals that target NF-AT activity in T cells. J. Immunol. 2005;174:7075–7084
  67. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, et al. CD95 promotes tumour growth. Nature. 2010;465:492–496

PII: S0304-3835(10)00363-0

doi: 10.1016/j.canlet.2010.07.015

« Back Cancer Letters

Article in Press

Article Tools

* Image Usage & Resolution